Cargando…

Adjuvant Application of Shenmai Injection for Sepsis: A Systematic Review and Meta-Analysis

OBJECTIVE: To compare the efficacy and safety of Shenmai injection plus regular treatment versus regular treatment alone in the treatment of sepsis. METHODS: Review Manager 5.3 was used. Databases including PubMed, Cochrane Library, Wan-FANG, VIP, CNKI, and CBM were searched for the relative control...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Ye, Liu, Yilin, Li, Li, Xue, Bing, Cao, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381209/
https://www.ncbi.nlm.nih.gov/pubmed/35983009
http://dx.doi.org/10.1155/2022/3710672
_version_ 1784769027359375360
author Sun, Ye
Liu, Yilin
Li, Li
Xue, Bing
Cao, Yan
author_facet Sun, Ye
Liu, Yilin
Li, Li
Xue, Bing
Cao, Yan
author_sort Sun, Ye
collection PubMed
description OBJECTIVE: To compare the efficacy and safety of Shenmai injection plus regular treatment versus regular treatment alone in the treatment of sepsis. METHODS: Review Manager 5.3 was used. Databases including PubMed, Cochrane Library, Wan-FANG, VIP, CNKI, and CBM were searched for the relative control and randomized studies till June 2022. Primary outcomes were 28-day mortality; case fatality rate; APACHE II score; and levels of procalcitonin, tumor necrosis factor-α, interleukin-6, and C-reaction protein. Secondary outcomes were measurements related to inflammatory reactions, coagulation function, immune function, and organ function. RESULTS: In total 21 studies with 1469 patients were included. Shenmai injection plus regular treatment of sepsis significantly decreased 28-day mortality rate (odds ratio: 0.36 (0.20, 0.63); p=0.0004) and case fatality rate (odds ratio: 0.32 (0.19, 0.54), p < 0.0001) and significantly further reduced APACHE II score (standard mean deviation: −1.14 (−1.30, 0.99); p < 0.00001). Procalcitonin reduction was similar in the two groups (standard mean deviation: −0.59 (−1.64, 0.46); p=0.27). Tumor necrosis factor-α (standard mean deviation: −1.96 (−2.79, −1.13); p < 0.00001), interleukin-6 (standard mean deviation: −1.52 (−2.13, −0.91); p < 0.00001), and C-reaction protein (standard mean deviation: −2.37 (−4.26, −0.49); p=0.01) levels were significantly further decreased in the Shenmai injection group. Most of the measurements related to inflammatory reaction, coagulation function, immune function, and organ function were significantly regulated in the Shenmai injection group. Furthermore, there was no adverse event, and two study groups had similar adverse event rates. CONCLUSION: Shenmai injection as adjuvant therapy shall be effective and safe in the treatment of sepsis. However, further investigation is still warranted especially regarding safety. Adjuvant application of Shenmai injection in sepsis is worth further investigation.
format Online
Article
Text
id pubmed-9381209
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-93812092022-08-17 Adjuvant Application of Shenmai Injection for Sepsis: A Systematic Review and Meta-Analysis Sun, Ye Liu, Yilin Li, Li Xue, Bing Cao, Yan Evid Based Complement Alternat Med Review Article OBJECTIVE: To compare the efficacy and safety of Shenmai injection plus regular treatment versus regular treatment alone in the treatment of sepsis. METHODS: Review Manager 5.3 was used. Databases including PubMed, Cochrane Library, Wan-FANG, VIP, CNKI, and CBM were searched for the relative control and randomized studies till June 2022. Primary outcomes were 28-day mortality; case fatality rate; APACHE II score; and levels of procalcitonin, tumor necrosis factor-α, interleukin-6, and C-reaction protein. Secondary outcomes were measurements related to inflammatory reactions, coagulation function, immune function, and organ function. RESULTS: In total 21 studies with 1469 patients were included. Shenmai injection plus regular treatment of sepsis significantly decreased 28-day mortality rate (odds ratio: 0.36 (0.20, 0.63); p=0.0004) and case fatality rate (odds ratio: 0.32 (0.19, 0.54), p < 0.0001) and significantly further reduced APACHE II score (standard mean deviation: −1.14 (−1.30, 0.99); p < 0.00001). Procalcitonin reduction was similar in the two groups (standard mean deviation: −0.59 (−1.64, 0.46); p=0.27). Tumor necrosis factor-α (standard mean deviation: −1.96 (−2.79, −1.13); p < 0.00001), interleukin-6 (standard mean deviation: −1.52 (−2.13, −0.91); p < 0.00001), and C-reaction protein (standard mean deviation: −2.37 (−4.26, −0.49); p=0.01) levels were significantly further decreased in the Shenmai injection group. Most of the measurements related to inflammatory reaction, coagulation function, immune function, and organ function were significantly regulated in the Shenmai injection group. Furthermore, there was no adverse event, and two study groups had similar adverse event rates. CONCLUSION: Shenmai injection as adjuvant therapy shall be effective and safe in the treatment of sepsis. However, further investigation is still warranted especially regarding safety. Adjuvant application of Shenmai injection in sepsis is worth further investigation. Hindawi 2022-08-09 /pmc/articles/PMC9381209/ /pubmed/35983009 http://dx.doi.org/10.1155/2022/3710672 Text en Copyright © 2022 Ye Sun et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Sun, Ye
Liu, Yilin
Li, Li
Xue, Bing
Cao, Yan
Adjuvant Application of Shenmai Injection for Sepsis: A Systematic Review and Meta-Analysis
title Adjuvant Application of Shenmai Injection for Sepsis: A Systematic Review and Meta-Analysis
title_full Adjuvant Application of Shenmai Injection for Sepsis: A Systematic Review and Meta-Analysis
title_fullStr Adjuvant Application of Shenmai Injection for Sepsis: A Systematic Review and Meta-Analysis
title_full_unstemmed Adjuvant Application of Shenmai Injection for Sepsis: A Systematic Review and Meta-Analysis
title_short Adjuvant Application of Shenmai Injection for Sepsis: A Systematic Review and Meta-Analysis
title_sort adjuvant application of shenmai injection for sepsis: a systematic review and meta-analysis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381209/
https://www.ncbi.nlm.nih.gov/pubmed/35983009
http://dx.doi.org/10.1155/2022/3710672
work_keys_str_mv AT sunye adjuvantapplicationofshenmaiinjectionforsepsisasystematicreviewandmetaanalysis
AT liuyilin adjuvantapplicationofshenmaiinjectionforsepsisasystematicreviewandmetaanalysis
AT lili adjuvantapplicationofshenmaiinjectionforsepsisasystematicreviewandmetaanalysis
AT xuebing adjuvantapplicationofshenmaiinjectionforsepsisasystematicreviewandmetaanalysis
AT caoyan adjuvantapplicationofshenmaiinjectionforsepsisasystematicreviewandmetaanalysis